hydroxyurea has been researched along with Blood Poisoning in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Hydroxyurea has been shown to reduce leukocyte counts, decrease inflammatory cytokines, and limit organ inflammation in ischemia-reperfusion models." | 8.12 | The effects of hydroxyurea on proinflammatory cytokine and tissue histopathology in an experimental sepsis model. ( Ergil, J; Kulturoglu, G; Kulturoglu, MO; Onder, EO; Yalcindag, A, 2022) |
| " Hydroxyurea has been shown to reduce leukocyte counts, decrease inflammatory cytokines, and limit organ inflammation in ischemia-reperfusion models." | 4.12 | The effects of hydroxyurea on proinflammatory cytokine and tissue histopathology in an experimental sepsis model. ( Ergil, J; Kulturoglu, G; Kulturoglu, MO; Onder, EO; Yalcindag, A, 2022) |
| " Our results, while no longer the product of a randomized study because of the ethical concerns of withholding an efficacious treatment, suggest that long-term use of hydroxyurea is safe and might decrease mortality." | 2.75 | The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. ( Armstrong, FD; Ataga, K; Ballas, SK; Castro, O; DeCastro, L; Kutlar, A; McCarthy, WF; Smith, W; Steinberg, MH; Swerdlow, P; Waclawiw, MA, 2010) |
| "Hydroxyurea therapy was used in 30 patients (31." | 1.36 | Sickle cell disease from Africa to Belgium, from neonatal screening to clinical management. ( Cotton, F; Dedeken, L; Dresse, MF; Ferster, A; Gulbis, B; Heijmans, C; Ketelslegers, O; Lê, PQ; Vanderfaeillie, A; Vermylen, C; Vertongen, F, 2010) |
| "Despite treatment for pulmonary hypertension and provision of respiratory support, the patient died." | 1.33 | Pulmonary hypertension in a child with juvenile myelomonocytic leukemia secondary to pulmonary leukemic cell infiltration. ( Alioglu, B; Demirhan, B; Erbay, A; Ozbek, N; Ozyurek, E; Varan, B, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kulturoglu, G | 1 |
| Ergil, J | 1 |
| Kulturoglu, MO | 1 |
| Yalcindag, A | 1 |
| Onder, EO | 1 |
| Bandyopadhyay, D | 1 |
| Manna, S | 1 |
| Hajra, A | 1 |
| Bhattacharya, TD | 1 |
| Steinberg, MH | 1 |
| McCarthy, WF | 1 |
| Castro, O | 1 |
| Ballas, SK | 1 |
| Armstrong, FD | 1 |
| Smith, W | 1 |
| Ataga, K | 1 |
| Swerdlow, P | 1 |
| Kutlar, A | 1 |
| DeCastro, L | 1 |
| Waclawiw, MA | 1 |
| Lê, PQ | 1 |
| Ferster, A | 1 |
| Cotton, F | 1 |
| Vertongen, F | 1 |
| Vermylen, C | 1 |
| Vanderfaeillie, A | 1 |
| Dedeken, L | 1 |
| Heijmans, C | 1 |
| Ketelslegers, O | 1 |
| Dresse, MF | 1 |
| Gulbis, B | 1 |
| Alioglu, B | 1 |
| Demirhan, B | 1 |
| Ozyurek, E | 1 |
| Varan, B | 1 |
| Erbay, A | 1 |
| Ozbek, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Hemostatic Potential in Sickle Cell Disease Patients[NCT02565082] | 64 participants (Actual) | Interventional | 2015-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for hydroxyurea and Blood Poisoning
| Article | Year |
|---|---|
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up.
Topics: Adolescent; Adult; Anemia, Sickle Cell; DNA Damage; Drug Utilization; Early Termination of Clinical | 2010 |
4 other studies available for hydroxyurea and Blood Poisoning
| Article | Year |
|---|---|
The effects of hydroxyurea on proinflammatory cytokine and tissue histopathology in an experimental sepsis model.
Topics: Animals; Cytokines; Hydroxyurea; Inflammation; Rats; Sepsis; Tumor Necrosis Factor-alpha | 2022 |
Atypical CML with massive splenic infarct: an extremely rare presentation.
Topics: Abdominal Pain; Anemia; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Fatal Outcom | 2015 |
Sickle cell disease from Africa to Belgium, from neonatal screening to clinical management.
Topics: Adolescent; Africa; Anemia, Sickle Cell; Antisickling Agents; Belgium; Bone Marrow Transplantation; | 2010 |
Pulmonary hypertension in a child with juvenile myelomonocytic leukemia secondary to pulmonary leukemic cell infiltration.
Topics: Anti-Bacterial Agents; Child, Preschool; Combined Modality Therapy; Diagnostic Errors; Fatal Outcome | 2006 |